SECURE has been set up by the WHO and GARDP to expand access to essential antibiotics to treat drug-resistant bacterial infections in a sustainable, equitable and appropriate way.

SECURE will work directly with countries to understand their public health needs and challenges with access to antibiotics. It will also work through partnerships with organizations and entities already involved in procurement mechanisms to support sustainable and equitable access.

Our 4 key goals and objectives

Optimise country level antibiotic portfolios for treating drug-resistant infections

Improve transparency of information for antibiotic purchase decisions

Increase security of supply and market predictability through efficiencies

Steward new product introduction pathways to safeguard effectiveness of antibiotics

SECURE will improve access to antibiotics by

  • Optimizing antibiotics formularies in countries or harmonizing regional formularies

  • Developing supplier landscape maps per region for products with access challenges

  • Developing long term forecasts and criteria for stockpiles and supporting existing pooled procurement mechanisms to include access challenged antibiotics into their service offerings

  • Reducing prices for products which are less affordable

  • Developing operational guidance and processes to support stewarded introduction of new products in countries

The outcomes are increased availability, affordability, and appropriate use of prioritized antibiotics for patients and reduced number and/or duration of shortages.

The Impact will be reduced AMR related mortality in LMICs.

Expanding access to essential antibiotics

Our achievements to date

Engagement with countries, partners and other stakeholders including industry

Evaluated and published economic and procurement tools by modelling impact, costs

SECURE interventions defined based on access challenges by antibiotic archetype and criteria for proof of concept antibiotic portfolio defined

Review of regulatory and policy interventions to address supply shortages

Designing an antibiotic forecasting model and Cost of Good Sold analysis

Designing a market intelligence platform and supplier landscape

Developing new antibiotic introduction operational guidance